MTOR and lung carcinoma: It also found that FA derivative FXS-3 showed anticancer activity that resulted in enhanced death of lung cancer A549 cells via negatively controlling ERK/p38, AKT/mTOR, and MEK/ERK signaling pathways, which provides the crucial scientific foundation for the advancement of anticancer medications involving FA derivatives [123].